Beruflich Dokumente
Kultur Dokumente
Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop
and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope - Modify the therapeutic
portfolio by identifying discontinued projects and understanding the factors that drove them from
pipeline.
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173372/vancomycinresistant-enterococcus-faecium-infections-pipeline-review-h2-2015
Browse
Introduction 9
Global Markets Direct Report Coverage 9
Vancomycin-Resistant Enterococcus faecium Infections Overview 10
Therapeutics Development 11
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview 11
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis 12
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by
Companies 13
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by
Universities/Institutes 15
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies 19
Vancomycin-Resistant Enterococcus
Universities/Institutes 21
faecium
Infections
Products
under
Investigation
by
Alvogen Korea 23
Aphios Corporation 24
BioSource Pharm, Inc. 25
Cellceutix Corporation 26
Helix BioMedix, Inc. 27
Hsiri Therapeutics, LLC 28
LegoChem Biosciences, Inc 29
Lytix Biopharma AS 30
MGB Biopharma Limited 31
Microbiotix, Inc. 32
MicuRx Pharmaceuticals, Inc. 33
NovaBay Pharmaceuticals, Inc. 34
NovoBiotic Pharmaceuticals, LLC 35
Oragenics, Inc. 36
Sealife PHARMA GMBH 37
Sentinella Pharmaceuticals, Inc. 38
TAXIS Pharmaceuticals, Inc. 39
Wockhardt Limited 40
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
auriclosene - Drug Profile 50
Product Description 50
3
Mechanism of Action 50
R&D Progress 50
brilacidin tetrahydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BSPC-728 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
chrysophaentin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
closthioamide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Epimerox - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HB-1345 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
R&D Progress 68
MBX-1162 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MGBBP-3 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MRX-I - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MRX-IV - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MU-1140 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
NAI-107 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NAI-603 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SLP-0904 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SLP-0905 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
7
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110
Read More
http://www.idatainsights.com/reports-landing-page.php?id=173372/vancomycinresistant-enterococcus-faecium-infections-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects
10